Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9HCN6

UPID:
GPVI_HUMAN

ALTERNATIVE NAMES:
Glycoprotein 6

ALTERNATIVE UPACC:
Q9HCN6; Q9HCN7; Q9UIF2

BACKGROUND:
Glycoprotein 6, known for its critical function as a collagen receptor in platelet procoagulant activity, is integral to the coagulation process. It activates platelets, leading to thrombin and fibrin generation, essential for blood clotting. The protein's activity involves a complex signaling pathway with components like FcR gamma-chain, Src kinases, SYK, LAT, and PLCG2.

THERAPEUTIC SIGNIFICANCE:
Dysfunction in Glycoprotein 6 is associated with Bleeding disorder, platelet-type, 11, due to impaired platelet aggregation. Targeting the molecular mechanisms of Glycoprotein 6 offers promising avenues for therapeutic interventions in bleeding disorders and thrombosis prevention.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.